Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients
[EN] Immunotherapy has opened new avenues of treatment for patients with advanced non-small cell lung cancer (NSCLC) without previous hope of survival. Unfortunately, only a small percentage of patients benefit from it and there is not an effective biomarker to predict patients' response. S...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universitat Politècnica de València (UPV) |
| Repositorio: | RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia |
| Idioma: | inglés |
| OAI Identifier: | oai:dnet:riunet______::93d88b6c18f83d79f64d9b55d5eb737a |
| Acceso en línea: | https://riunet.upv.es/handle/10251/233693 |
| Access Level: | acceso abierto |
| Palabra clave: | Non-small cell lung cancer Pembrolizumab Predictive biomarker Immunotherapy response T cell receptor TCR repertoire |
| Sumario: | [EN] Immunotherapy has opened new avenues of treatment for patients with advanced non-small cell lung cancer (NSCLC) without previous hope of survival. Unfortunately, only a small percentage of patients benefit from it and there is not an effective biomarker to predict patients' response. Since T cells are key effectors of antitumor immunity, T cell receptor (TCR) has emerged as a potential predictive biomarker. Here, we evaluated the potential of baseline TCR repertoire, as a predictive biomarker in advanced NSCLC patients treated with pembrolizumab at first-line. After obtaining peripheral blood and tissue samples at baseline, next-generation sequencing targeting TCR beta/gamma was performed. We found an uneven tumor-infiltrating TCR beta repertoire, and the use of various tumor-infiltrating and circulating TRBV/J genes were able of predicting the immunotherapy response. Our results support the potential of evaluating tissue and circulating TCR beta repertoire prior to pembrolizumab, revealing it as a promising immunotherapy response biomarker in NSCLC patients. |
|---|